SCHEMBL2118106

SCHEMBL2118106

C=COC(=O)CCOP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
ADRA1A P35348 2/20 0.48
LMNA P02545 1/20 0.48
ESR1 P03372 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CDC25A P30304 1/20 0.48
AGTR1 P30556 1/20 0.48
AKT1 P31749 1/20 0.48
KCNH2 Q12809 1/20 0.48
NR5A2 O00482 1/20 0.44
NR5A1 Q13285 1/20 0.44
MAPT P10636 1/20 0.42
PLA2G1B P04054 1/20 0.41
PLA2G2A P14555 1/20 0.41
RECQL P46063 1/20 0.41
ADRA1D P25100 1/20 0.40
PTAFR P25105 1/20 0.40
HTR1D P28221 1/20 0.40
HTR2C P28335 1/20 0.40
ADRA1B P35368 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118767 0.86 SMN1; SMN2 (0.47) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL170993 0.78 LMNA (0.56) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL6437449 0.77 SMN1; SMN2 (0.55) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL9067683 0.76 LMNA (0.54) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL2118813 0.76 LMNA (0.53) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL139079 0.75 SMN1; SMN2 (0.49) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL1856364 0.74 LMNA (0.51) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL9067475 0.73 SMN1; SMN2 (0.48) SMN1; SMN2ADRA1ALMNAESR1ADORA3
Phosphocholine SCHEMBL10948480 0.73 SMN1; SMN2 (0.46) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL15312730 0.73 ADRA1A (0.58) SMN1; SMN2ADRA1ALMNAESR1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121802-B1 HIGH REFRACTIVE INDEX SILOXANE INSERT MATERIALS FOR EMBEDDED CONTACT LENSES ALCON INC (CH) 2024-07-17 EP claimed
EP-4121801-B1 INSERT MATERIALS WITH HIGH OXYGEN PERMEABILITY AND HIGH REFRACTIVE INDEX ALCON INC (CH) 2024-04-17 EP claimed
EP-4146461-B1 METHOD FOR PRODUCING SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2024-03-13 EP claimed
EP-3774310-B1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2022-07-06 EP claimed
EP-3746820-B1 CONTACT LENSES WITH A LUBRICIOUS COATING THEREON ALCON INC (CH) 2022-02-16 EP claimed
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME KCI CO., LTD. (KR) 2014-09-25 US claimed
EP-0537972-B1 Treating solution for contact lenses NOF CORP (JP) 1996-07-10 EP claimed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US claimed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP claimed
US-11029446-B2 Method for producing MPS-compatible water gradient contact lenses ALCON INC. (CH) 2021-06-08 US disclosed
US-20190176415-A1 METHOD FOR PRODUCING MPS-COMPATIBLE WATER GRADIENT CONTACT LENSES ALCON INC. (CH) 2019-06-13 US disclosed
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME KCI CO., LTD. (KR) 2014-09-25 US disclosed
EP-2772247-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME KCI Co.,ltd (KR) 2014-09-03 EP disclosed
EP-2660252-A2 POLYSACCHARIDE-BASED GRAFT COPOLYMER AND COMPOSITION COMPRISING SAME FOR PERSONAL CARE Kci Limited (KR) 2013-11-06 EP disclosed
US-8318824-B2 Hydrophilic polyolefin sintered body ASAHI KASEI CHEMICALS CORPORATION (JP) 2012-11-27 US disclosed
US-20120095121-A1 HYDROPHILIC POLYOLEFIN SINTERED BODY ASAHI KASEI CHEMICALS CORPORATION (JP) 2012-04-19 US disclosed
EP-2174975-A1 HYDROPHILIC POLYOLEFIN SINTERED BODY Asahi Kasei Chemicals Corporation (JP) 2010-04-14 EP disclosed
EP-0537972-B1 Treating solution for contact lenses NOF CORP (JP) 1996-07-10 EP disclosed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US disclosed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME C1QBP, PCTP, CD59 SMN1; SMN2 4469/4885ADRA1A 1776/4885LMNA 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.